Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma

Clinical Lymphoma

Volumn 4, Issue 1, 2003, Pages 43-49

  Blum, Robert H ^a   Seymour, John F ^a   Wirth, Andrew ^a   MacManus, Michael ^a   Hicks, Rodney J ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Computed tomography; Disease progression; Follicular lymphoma; Functional imaging; Structural imaging; Tumor staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MEDICAL RECORD; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLICULAR LYMPHOMA; LABORATORY DIAGNOSIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037677687     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2003.n.013     Document Type: Article

References (42)

1. Bastion Y, Berger F, Bryon PA, et al. Follicular lymphoma: assessment of prognostic factors in 127 patients followed for 10 years. Ann Oncol 1991; 2 (suppl 2):123-129.
2. Bastion Y, Sebban C, Berger F, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997;15:1587-1594.
3. Armitage JO, Mauch P, Harris NL, et al. Non Hodgkin's lymphoma. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds: Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:859-1927.
4. Cabanillas F, Horning S, Kaminski M, et al. Managing indolent lymphomas in relapse: working our way through a plethora of options. In: Schechter GP, Berliner N, Telen MJ. Hematology 2000: American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology, 2000:166-179.
5. Ngan BY, Chen-Levy Z, Weiss LM, et al. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 1988; 318:1638-1644.
6. Lawrence TS, Urba WJ, Steinberg SM, et al. Retrospective analysis of stage I and II indolent lymphomas at the National Cancer Institute. Int J Radiat Oncol Biol Phys 1988; 14:417-424.
7. MacManus MP, Hoppe RT. Is radiotherapy curative for stage I and II low grade lymphoma? Results of a long-term follow-up of patients at Stanford University. J Clin Oncol 1996; 14:1282-1290.
8. Paryani SB, Hoppe RT, Cox RS, et al. Analysis of non-Hodgkin's lymphoma with nodular and favorable stages I and II. Cancer 1983; 52:2300-2307.
9. Vaughan HB, Vaughan HG, MacLennan KA, et al. Clinical stage I non-Hodgkin's lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br J Cancer 1994; 96:1088-1093.
10. Gospodarowicz MK, Bush RS, Brown TC, et al. Prognostic factors in nodular lymphoma: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 1984; 10:489-497.
11. Seymour JF, McLaughlin P, Fuller LM, et al. High rate of prolonged remission following combined modality therapy for patients with localized low-grade lymphoma. Ann Oncol 1996; 7:157-163.
12. Chaffey JT, Hellman S, Rosenthal DS, et al. Total-body irradiation in the treatment of lymphocytic lymphoma. Cancer Treat Rep 1977; 67:1149-1152.
13. Murtha AD, Knox SJ, Hoppe RT, et al. Long-term follow-up of patients with stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys 2001; 49:3-15.
14. Jacobs JP, Murray KJ, Schultz CJ, et al. Central Lymphatic irradiation for stage III nodular malignant lymphoma: long-term results. J Clin Oncol 1993; 11:233-238.
15. Ha CS, Cabanillas F, Lee MS, et al. Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report. Clin Cancer Res 1997; 3:215-219.
16. Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy and conventional staging for Hodgkin's and non-Hodgkin's lymphoma. Am J Med 2002; 112:262-268.
17. Ben-Haim S, Bar-Shalom R, Israel O, et al. Utility of gallium-67 scintigraphy in low grade non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:1936-1942.
18. Robert P. Comparison of Fluorine-18-2-fluorodeoxyglucose and Gallium-67 citrate imaging for detection of lymphoma. J Nucl Med 1987; 28:288-292.
19. Larcos G, Farlow DC, Antico VF, et al. The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. Aust N Z J Med 1994; 24:5-8.
20. Mansberg R,Wadhwa SS, Mansberg V.T1-201 and Ga-67 scintigraphy in non-Hodgkin's lymphoma. Clin Nucl Med 1999; 24:239-242.
21. Scott AM. Current status of positron emission tomography in oncology. Intern Med J 2001; 31:27-36.
22. Talbot JN, Haioun C, Rain JD, et al. [18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38:193-221.
23. Kostakoglu L, Goldsmith SJ. Flourine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000; 27:1564-1578.
24. Jaffe ES, Harris NL, Stein H, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer Press, 2001: 119-185.
25. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease. Cotswolds meeting. J Clin Oncol 1989; 7:1630-1636.
26. Leskinen-Kallio S, Ruotsalainen U, Nagren K, et al. Uptake of carbon-11 methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. J Nucl Med 1991; 32:1211-1218.
27. Hoffman M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185-1189.
28. McLaughlin P, Fuller LM, Velasquez WS, et al. Stage III follicular lymphoma: durable remission with a combined chemotherapy-radiotherapy regimen. J Clin Oncol 1987; 5:867-874.
29. MacManus M, Hicks RJ, Ball DL, et al. F-18 Fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with non-small cell lung carcinoma. Cancer 2001; 92:886-895.
30. MacManus M, Hicks RJ, Matthews JP, et at. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50:1-7.
31. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnosis of oncology patients. Eur J Nucl Med 1996; 23:1409-1415.
32. Wahl RL, Henry CA, Ethier SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 1992; 183:643-647.
33. Vitale GD, deKemp RA, Ruddy TD, et al. Myocardial glucose utilization and optimization of (18) F-FDG PET imaging in patients with noninsulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction. J Nucl Med 2001; 42:1730-1736.
34. Leeds NE, Jackson EF. Current imagining techniques for the evaluation of brain neoplasms. Curr Opin Oncol 1994; 6:254-264.
35. Rodriguez M. Computer tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma. Acta Radiol Suppl 1998; 417:1-36.
36. Godersky JC, Smoker WR, Knutzon R. Use of magnetic resonance imagining in the evaluation of metastatic spinal disease. Neurosurgery 1987; 21:676-680.
37. North LB, Wallace S, Lindell MM Jr, et al. Lymphography for staging lymphoma: is it still a useful procedure? AJR Am J Roentgenol 1993; 161:867-869.
38. Castellino RA, Dunnick NR, Goffinet DR, et al. Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1983; 1:532-536.
39. Goffinet DR, Warnke R, Dunnick NR, et al. Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphoma. Cancer Treat Rep 1977; 61:981-992.
40. Heifetz LJ, Fuller LM, Rodgers RW, et al. Laparotomy findings in lymphangiogram-stage I and II non-Hodgkin's lymphomas. Cancer 1980; 45:2778-2786.
41. Newman JS, Francis IR, Kaminski MS, et al. Imaging of lymphoma with PET with 2-[F-18]-fluro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190:111-116.
42. Kostakoglu L, Leonard JP, Coleman M, et al. Comparison of fluorine-18 deoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer 2002; 94:879-888.